Sanofi Pasteur Biologics, LLC

Sanofi Pasteur Inc.

Oregon Health & Science University

Acambis Inc.

Oravax-merieux Co.

Sanofi Pasteur Biologics Co.

Harold Kleanthous

Farshad Guirakhoo

Pierre Garrone

Stephen F Anderson

Donald Martin Carter, Jr

Tim Alefantis

Nicola Beltraminelli

Jianxin Zhang

Alexander A Rumyantsev

Ted Milburn Ross

Natalie Anosova

Christopher Austin Darby

Majid Mehtali

Thomas P Monath

Simon Delagrave

Konstantin V Pugachev

Cynthia K Lee

Yanhua Yan

Maryann Giel-Moloney

Nathan Brown

Kirill Kalnin

Samuel K Ackerman

Mark Parrington

Tod Dwayne Strugnell

Eliud Oloo

Raymond Oomen

Richard A Weltzin

Linong Zhang

Hitesh Bhagat

Charles Miller

Gopalan Soman

William D Thomas

Jacques Pappo

Thorsten Vogel

Larisa Oros

Patricia Londono-Arcila

Donna Freeman

Ilene Sussman

Thomas Ermak

Monoclonal antibodies, or antigen-binding fragments thereof, that bind to() toxin A or toxin B and methods of using the same to detect or treatinfections and/or-associated disease.

Antibodies against clostridium difficile toxins and methods of using the same

The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.

Methods of generating broadly protective vaccine compositions comprising hemagglutinin

Antibodies againsttoxins and methods of using the same

Co-administration (for example, immunogenic cocktail compositions and/or prime boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides is provided. Coadministration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (for example, a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.

Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza

The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.

Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza

The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.

Monoclonal antibodies or antigen-binding fragments thereof, that bind to() toxin A or toxin B and methods of using the same to detect or treatinfections and/or-associated disease.is a gram positive, anaerobic bacterium that causes gastrointestinal disease in humans. The bacteria are transmitted through feces and spread to food and other surfaces when people who are infected do not thoroughly wash their hands.

[object Object]

The invention relates to methods and compositions for preventing or treating human rhinovirus infection.

Neutralizing immunogen (NimIV) of rhinovirus and its uses for vaccine applications

This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.

Recombinant bicistronic flavivirus vectors

This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.

Replication-defective flavivirus vaccines and vaccine vectors

The invention relates to methods and compositions for preventing or treating humaninfection.

Neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications

The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.

Chimeric flavivirus vectors

The invention provides a method of immunization against Helicobacter, involving mucosal administration of an attenuated Salmonella vector including a nucleic acid molecule encoding a Helicobacter antigen, and parenteral administration of a soluble Helicobacter antigen, co-administered with a suitable parenteral adjuvant. Also provided by the invention are attenuated Salmonella vectors for use in this method.

Use of Salmonella vectors for vaccination against helicobacter infection

Growing community of inventors

Westford, MA, United States of America

Harold Kleanthous